Vape Industry Weekly: June Week 3 — Top 7 Stories

Quick Overview

This was a week where the science and politics of vaping both sharpened in opposing directions. A major UNSW review concluded that vaping is likely carcinogenic to humans — the strongest academic statement yet on long-term risk. Meanwhile, the FDA’s internal chaos spilled into public view as AP revealed senior regulators were blindsided by their own enforcement guidance. And Palau took the extraordinary step of asking the UN to classify nicotine alongside narcotics. Three very different stories, but they share a thread: the regulatory and scientific ground is shifting under the vaping industry faster than most people realize.

1. Major Review Finds Vaping Likely Causes Lung and Oral Cancer

The most consequential health story of the week came from UNSW Sydney, publishing in Carcinogenesis. The review found consistent evidence across clinical monitoring, animal studies, and lab data that e-cigarettes are likely to cause lung and oral cancer. Key findings include multiple carcinogens in aerosols (VOCs and metals from heating coils), biomarkers showing DNA damage and inflammation in vapers, and mouse studies that resulted in lung tumors. Dual users — people who both vape and smoke — face a 4x increased lung cancer risk. The researchers drew direct parallels to early smoking research, warning against repeating the 80-year delay in recognizing smoking risks.

This follows closely on the Nature Medicine study published earlier in June that found former smokers who switched to vaping still faced 23% higher lung cancer risk than those who quit nicotine entirely. Together, these studies are reshaping the harm reduction debate — shifting the question from “safer than smoking?” to “safe enough to use long-term?”

2. Palau Asks UN to Classify Nicotine as a Narcotic

The Republic of Palau formally requested the United Nations to review nicotine for addition to the list of controlled substances alongside narcotics and psychotropic drugs. If successful, this would effectively make non-medicinal nicotine products illegal globally. Palau’s first lady Valerie Whipps cited youth vaping rates — 29% of Palauan adolescents aged 9-20 had used vapes in 2021. The nation already banned vapes in 2023. Experts consider UN approval unlikely given tobacco industry opposition, but the symbolic weight is significant: this is the first UN-level challenge to nicotine’s legal status.

3. FDA Enforcement Policy Blindsided Its Own Regulators

AP News revealed that senior FDA tobacco center officials were blindsided by the May 2026 enforcement discretion guidance. Staffers were not consulted and only learned of the changes the night before publication. The six-page memo breaks with longstanding FDA policy requiring scientific verification before new products launch. Internal meetings have been held to grapple with implementation. The guidance was posted days before former FDA Commissioner Marty Makary resigned. For context on what this means for products on shelves, see our breakdown of the FDA’s new enforcement policy and the vape seize and destroy law.

4. Fifth Circuit Pressures FDA on Flavored Vape Logic

The Fifth Circuit Court of Appeals grilled FDA attorneys over whether the agency improperly adopted a de facto regulatory standard requiring flavored vape manufacturers to prove their products are more effective at helping smokers quit than tobacco flavors. This requirement led to over a million flavored vapes being pulled from shelves since 2021. Research from Yale, Georgetown, and UCL shows adults who quit smoking tend to prefer non-tobacco flavors, while youth vaping rates have fallen to just over 5% (2025 NYTS). We covered the Fifth Circuit hearing in detail.

5. UK Vaping Duty to Generate £565M by 2030

The UK will introduce its Vaping Products Duty on October 1, 2026, applying to all vaping liquids including nicotine-free. Receipts are projected to grow from £135M in FY2026/27 to £565M by 2030/31. Travelers 17+ can bring 50ml duty-free; more than 50ml requires declaration and duty on the entire quantity. Northern Ireland has different rules due to EU market access. The duty arrives alongside the Tobacco and Vapes Act, which creates a generational tobacco sales ban and gives ministers wide powers over vape advertising and packaging.

6. ‘Ice’ Vape Flavors May Have Hidden Heart Effects

Research published in the Journal of the American Heart Association found that menthol and synthetic cooling agents (WS-3, WS-23) activate TRPM8 receptors found throughout the body. A mouse study found menthol-containing e-cigarette aerosols raised heart rate, blood pressure, and ventricular premature beats. Epinephrine levels increased, and some effects persisted weeks after exposure. Laboratory studies also show flavor chemicals can damage blood vessel lining cells even without nicotine. This is an animal study — human studies are needed — but it raises questions about the safety profile of cooling agents used in most disposable vapes.

7. France Criminalizes Nicotine Pouches — European Crackdown Spreads

France’s ban on nicotine pouches now carries penalties up to 5 years in prison and hundreds of thousands in fines for production, importation, possession, transport, distribution, and use. Swedish Trade Minister called the policy “absurd.” Meanwhile, the Netherlands is raising the nicotine purchase age to 21, Portugal approved flavor bans and online sales restrictions on pouches, and Spain is considering restricting vape sales to specialist retailers while cigarettes remain widely available. The contrast with the FDA’s first-ever authorization of fruit-flavored vapes in the US highlights a growing transatlantic divide in nicotine policy philosophy.

Weekly Trends & Analysis

The dominant theme this week is that the scientific evidence on vaping health risks is hardening — and the regulatory response is fragmenting. The UNSW Carcinogenesis review and the Nature Medicine study together represent the strongest academic case yet that vaping carries real long-term cancer risk, not just the “safer than smoking” framing the industry prefers. This is going to make it harder for harm reduction advocates to argue that vaping should be treated differently from other tobacco products.

At the same time, the FDA’s internal dysfunction — staffers not consulted on their own enforcement policy — suggests the agency is struggling to find a coherent path forward. The Fifth Circuit challenge adds legal pressure. And Palau’s UN gambit, while unlikely to succeed, signals that prohibitionist forces are looking for new levers beyond national regulation.

The takeaway: the window for a science-based, balanced regulatory approach is narrowing. Both the prohibitionist and the laissez-faire camps are gaining momentum, and the middle ground is getting squeezed.

What to Watch Next Week

The Fifth Circuit’s ruling on the FDA flavor policy challenge could come any day — that’s the single biggest near-term regulatory event. Also watch for: the UK’s VPD implementation timeline as October approaches, whether more European countries follow France’s extreme approach to pouches, and any FDA response to the internal chaos revealed by AP. On the science side, expect follow-up coverage of the UNSW review and pushback from industry-funded researchers.